You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽託生物(300583.SZ):子公司獲得《藥品生產許可證》
格隆匯 07-20 19:39

格隆匯 7 月 20日丨賽託生物(300583.SZ)公告,近日收到控股子公司山東斯瑞藥業有限公司(以下簡稱“斯瑞藥業”)的通知,其獲得了山東省藥品監督管理局頒發的《藥品生產許可證》。

本次系控股子公司斯瑞藥業首次獲發《藥品生產許可證》,完善了原料藥生產平台,優化了公司產業結構,有利於公司原料藥產業的發展。同時對實現公司“醫藥中間體、原料藥、製劑”一體化的產業鏈延伸戰略、提高公司核心競爭力具有積極意義。本次斯瑞藥業獲得《藥品生產許可證》,短期內不會對公司業績產生重大影響,敬請廣大投資者理性投資,注意投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account